Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $130.
September 20, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Charles Duncan has reiterated an Overweight rating for Intra-Cellular Therapies, maintaining a price target of $130. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and a $130 price target by a reputable analyst suggests a positive outlook for ITCI, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100